Previous 10 | Next 10 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid det...
2024-05-06 23:43:05 ET T2 Biosystems, Inc. (TTOO) Q1 2024 Earnings Conference Call May 06, 2024, 04:30 PM ET Company Participants Philip Taylor - IR, Gilmartin Group John Sperzel - Chairman & CEO John Sprague - CFO Conference Call Participants Kyl...
2024-05-06 16:42:11 ET More on T2 Biosystems T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript T2 Biosystems GAAP EPS of -$2.66, revenue of $2.06M T2 Biosystems shareholders vote to convert $15M CRG debt into equity Read the full article on Seekin...
2024-05-06 16:39:51 ET More on T2 Biosystems T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript T2 Biosystems shareholders vote to convert $15M CRG debt into equity T2 Biosystems receives extension to comply with Nasdaq listing requirement Seeking Al...
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter e...
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid de...
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid det...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
2024-05-03 17:20:24 ET More on T2 Biosystems T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript T2 Biosystems shareholders vote to convert $15M CRG debt into equity T2 Biosystems receives extension to comply with Nasdaq listing requirement Seeking Al...
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after mar...
News, Short Squeeze, Breakout and More Instantly...
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (ȁ...
2024-05-17 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregat...